Core Insights - Vivos Inc. has been granted U.S. Patent No. 12,521,452 B2 for its innovative cancer treatment technology, specifically a radioactive thermogel suspension that enhances its Precision Radionuclide TherapyTM platform [1][2] Patent and Technology - The patent protects a novel thermosensitive PLGA-g-PEG hydrogel combined with yttrium-90 particles, allowing for precise, localized radiation delivery to solid tumors while minimizing damage to healthy tissue [2] - The gel remains injectable at room temperature and solidifies at body temperature, ensuring effective immobilization of the radiation source [2] Intellectual Property Developments - Vivos has received approval for its PRECISIONGEL™ trademark in the U.S. and New Zealand, and has filed a new patent application to further protect its hydrogel technology [3] - The new application covers the hydrogel's use as a carrier for various therapeutic agents, reinforcing the company's position in advanced hydrogel-based delivery systems [3] Strategic Vision - The CEO of Vivos Inc. emphasized that these milestones significantly enhance the company's intellectual property portfolio, supporting clinical progress and potential strategic partnerships [4] - The focus on building a strong IP position is aimed at driving shareholder value and enabling global commercial expansion [4] Company Overview - Vivos Inc. is a clinical-stage medical device company developing RadioGel® for human oncology and IsoPet® for veterinary applications, with IsoPet® already available in certified clinics across the nation [5]

Core Insights - Vivos Inc. has appointed Dr. John J. Smith and his team at Hogan Lovells as lead regulatory advisors for the FDA Investigational Device Exemption (IDE) submission for RadioGel® [1][3] Company Overview - Dr. John J. Smith is a board-certified diagnostic radiologist and a recognized FDA regulatory consultant in the medical device sector, currently a partner at Hogan Lovells in Washington, D.C. [2] - The CEO of Vivos Inc., Dr. Michael Korenko, expressed confidence in re-engaging Dr. Smith due to his familiarity with RadioGel® and his expertise in navigating the FDA's review process [3] Product Information - RadioGel® is an innovative injectable device designed to deliver high-dose, localized radiation to tumors safely and effectively [3] - Securing IDE approval is crucial for Vivos Inc. to initiate U.S. clinical trials at the Mayo Clinic, as RadioGel® is not yet authorized for pre-market use [3]